(UroToday.com) Dr. Tetsutaro Hayashi, Hiroshima University Department of Urology, Hiroshima, Japan presented “Transition of ANX10 expression is a useful diagnostic and prognostic marker in upper tract urothelial carcinoma (UTUC).” There exists a relative paucity of informative biomarkers for UTUC compared to bladder urothelial carcinoma. Dr. Hayashi et al. investigated ANXA10 as a potential biomarker for UTUC. In a cohort of 117 nephroureterectomy specimens, ANXA10 was preferentially expressed in urothelial carcinoma compared to normal tissues, and this expression was lost in more poorly differentiated tumors with increasing stage and grade. Expression loss was also associated with adverse survival outcomes. The investigators establish ANXA10 as both a diagnostic and prognostic biomarkers in UTUC which warrants prospective validation.
Presented by: Tetsutaro Hayashi, MD, Ph.D., Hiroshima University Department of Urology, Hiroshima, Japan
Written by: Dr. Patrick Hensley, Urologic Oncology Fellow at MD Anderson Cancer Center, Twitter: @pjhensley11, with Ashish Kamat, MD, MBBS, President of The International Bladder Cancer Network (IBCN), The International Bladder Cancer Group (IBCG), and Professor of the Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, Twitter: @UroDocAsh, at the International Bladder Cancer Network (IBCN) Annual Meeting, #IBCN2020, October 17, 2020.